Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

Maria Vittoria Dieci; Monica Arnedos; Fabrice Andre; Jean Charles Soria

doi:10.1158/2159-8290.CD-12-0362

Review

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

Maria Vittoria Dieci, Monica Arnedos, Fabrice Andre and Jean Charles Soria

Maria Vittoria Dieci

1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Monica Arnedos

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fabrice Andre

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean Charles Soria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/2159-8290.CD-12-0362 Published March 2013

Article
Figures & Data
Info & Metrics
PDF

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2013 to April 2021

	Abstract	Full-text HTML	PDF
Total	7802	7512	6923

Cited By

Article Information

Volume 3, Issue 3, pp. 264-279

DOI

https://doi.org/10.1158/2159-8290.CD-12-0362

PubMed

23418312

Published By

American Association for Cancer Research

Print ISSN

2159-8274

Online ISSN

2159-8290

History

Received August 1, 2012
Revision received November 27, 2012
Accepted November 30, 2012
Published first February 15, 2013.

Article Versions

Previous version (February 15, 2013 - 06:30).
You are viewing the most recent version of this article.

Author Information

Maria Vittoria Dieci1,3,5,
Monica Arnedos1,3,
Fabrice Andre1,3,4 and
Jean Charles Soria2,3,4

Authors' Affiliations:¹Breast Cancer Unit and ²Early Drug Development Unit (SITEP), Department of Medical Oncology; ³INSERM Unit U981, Gustave Roussy Institute, Villejuif; ⁴Paris Sud University, Orsay, France; and ⁵Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy

Corresponding Author:
Fabrice Andre, Comité 050, Gustave Roussy Institute, 114 rue E Vaillant, 94800 Villejuif, France. Phone: 003-314-211-4371; Fax: 003-314-211-5274; E-mail: fandre{at}igr.fr

View Full Text

PreviousNext

March 2013
Volume 3, Issue 3

Table of Contents
Table of Contents (PDF)
About the Cover

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

Message Subject (Your Name) has forwarded a page to you from Cancer Discovery

Message Body (Your Name) thought you would be interested in this article in Cancer Discovery.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives